[{"id":"28d28f42-9a11-470f-aad6-b354ed154518","acronym":"PULMO-01","url":"https://clinicaltrials.gov/study/NCT06879717","created_at":"2025-09-07T02:00:11.544Z","updated_at":"2025-09-07T02:00:11.544Z","phase":"Phase 1/2","brief_title":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06879717 - PULMO-01","lead_sponsor":"iOnctura","biomarkers":" IL7R","pipe":"","alterations":" ","tags":["IL7R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Jemperli (dostarlimab-gxly) • roginolisib (IOA-244)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/22/2025","start_date":" 04/22/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-05-13"},{"id":"ab61b8a8-7577-42c8-aace-25d2ec073ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700721","created_at":"2023-01-26T15:02:55.768Z","updated_at":"2025-02-25T14:09:25.231Z","phase":"Phase 2","brief_title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","source_id_and_acronym":"NCT05700721","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 08/07/2025","primary_completion_date":" 08/07/2025","study_txt":" Completion: 08/07/2027","study_completion_date":" 08/07/2027","last_update_posted":"2025-02-17"},{"id":"ac98599e-66be-47cf-ae0f-233b9edd3aa9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06405230","created_at":"2024-05-08T20:30:26.111Z","updated_at":"2025-02-25T14:19:04.825Z","phase":"Phase 1/2","brief_title":"Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06405230","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Jemperli (dostarlimab-gxly)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 12/16/2027","primary_completion_date":" 12/16/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-17"},{"id":"efdddd68-b037-4a5e-906c-80c7cd541d58","acronym":"DOVE","url":"https://clinicaltrials.gov/study/NCT06023862","created_at":"2023-09-05T18:12:37.255Z","updated_at":"2025-02-25T13:13:29.101Z","phase":"Phase 2","brief_title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","source_id_and_acronym":"NCT06023862 - DOVE","lead_sponsor":"Yonsei University","biomarkers":" MSI • PD-1 • WT1","pipe":"","alterations":" ","tags":["MSI • PD-1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/22/2024","start_date":" 01/22/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-14"},{"id":"2c6b4f69-4124-49bc-8cc4-6915ea81dc11","acronym":"INDUCE-1","url":"https://clinicaltrials.gov/study/NCT02723955","created_at":"2021-01-17T17:58:41.023Z","updated_at":"2025-02-25T16:04:31.793Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","source_id_and_acronym":"NCT02723955 - INDUCE-1","lead_sponsor":"GlaxoSmithKline","biomarkers":" MSI • ICOS","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • pemetrexed • Jemperli (dostarlimab-gxly) • bintrafusp alfa (M7824) • cobolimab (TSR-022) • feladilimab (GSK3359609) • GSK3174998"],"overall_status":"Completed","enrollment":" Enrollment 829","initiation":"Initiation: 06/23/2016","start_date":" 06/23/2016","primary_txt":" Primary completion: 07/05/2023","primary_completion_date":" 07/05/2023","study_txt":" Completion: 07/05/2023","study_completion_date":" 07/05/2023","last_update_posted":"2024-12-27"},{"id":"8cbc9df2-3083-40e5-bec9-7132199e2c56","acronym":"DOMENICA","url":"https://clinicaltrials.gov/study/NCT05201547","created_at":"2022-01-21T13:53:31.533Z","updated_at":"2025-02-25T13:12:52.274Z","phase":"Phase 3","brief_title":"Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line","source_id_and_acronym":"NCT05201547 - DOMENICA","lead_sponsor":"ARCAGY/ GINECO GROUP","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-11-25"},{"id":"52596305-5825-4a69-9da4-f4d1348c8313","acronym":"","url":"https://clinicaltrials.gov/study/NCT04774419","created_at":"2021-03-01T14:52:30.559Z","updated_at":"2025-02-25T13:19:57.496Z","phase":"Phase 2","brief_title":"Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery","source_id_and_acronym":"NCT04774419","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • POLE mutation","tags":["MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-11-11"},{"id":"28c1fd40-f94e-4cca-b4b5-626fe1cac96a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04673448","created_at":"2021-01-19T20:45:05.881Z","updated_at":"2025-02-25T13:19:47.405Z","phase":"Phase 1","brief_title":"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04673448","lead_sponsor":"University of Washington","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-11-08"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"e073adbc-974d-423b-b408-1f0614b44b3b","acronym":"TBCRC 056","url":"https://clinicaltrials.gov/study/NCT04584255","created_at":"2021-01-18T21:52:19.886Z","updated_at":"2025-02-25T13:19:39.281Z","phase":"Phase 2","brief_title":"Niraparib + Dostarlimab in BRCA Mutated Breast Cancer","source_id_and_acronym":"NCT04584255 - TBCRC 056","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 07/17/2025","primary_completion_date":" 07/17/2025","study_txt":" Completion: 07/17/2029","study_completion_date":" 07/17/2029","last_update_posted":"2024-09-19"},{"id":"eb48a20f-88f5-4d35-a3ff-283774b15fd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06065462","created_at":"2023-10-04T16:11:21.780Z","updated_at":"2025-02-25T13:13:30.456Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100","source_id_and_acronym":"NCT06065462","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly) • LB-100"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/10/2023","start_date":" 11/10/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-08-28"},{"id":"c51f002e-ce44-4d9e-90a8-e07fc75096f3","acronym":"PREDOSTAR","url":"https://clinicaltrials.gov/study/NCT05855811","created_at":"2023-05-11T14:04:51.969Z","updated_at":"2025-02-25T13:13:21.169Z","phase":"Phase 2","brief_title":"PREventing Second Cancers With DOSTARlimab","source_id_and_acronym":"NCT05855811 - PREDOSTAR","lead_sponsor":"Centre Leon Berard","biomarkers":" TP53 • BRCA • IL2","pipe":" | ","alterations":" TP53 mutation • BRCA mutation","tags":["TP53 • BRCA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/26/2028","primary_completion_date":" 07/26/2028","study_txt":" Completion: 03/26/2029","study_completion_date":" 03/26/2029","last_update_posted":"2024-07-15"},{"id":"3d93b394-a76f-412d-8318-5dfa5e8d3b54","acronym":"ENGOT-0V44","url":"https://clinicaltrials.gov/study/NCT03602859","created_at":"2021-01-18T17:42:44.526Z","updated_at":"2024-07-02T16:34:59.099Z","phase":"Phase 3","brief_title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03602859 - ENGOT-0V44","lead_sponsor":"Tesaro, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1402","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 10/25/2024","primary_completion_date":" 10/25/2024","study_txt":" Completion: 06/22/2026","study_completion_date":" 06/22/2026","last_update_posted":"2024-06-04"},{"id":"aa16b55b-d9d1-45a5-8a5d-621949c72998","acronym":"","url":"https://clinicaltrials.gov/study/NCT04165772","created_at":"2021-01-18T20:19:38.758Z","updated_at":"2025-02-25T13:19:11.319Z","phase":"Phase 2","brief_title":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors","source_id_and_acronym":"NCT04165772","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/11/2019","start_date":" 12/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-04-23"},{"id":"691969a6-dc3e-4580-99bb-0a9ff4f0cef1","acronym":"NIRADO","url":"https://clinicaltrials.gov/study/NCT04779151","created_at":"2021-03-03T13:57:08.218Z","updated_at":"2024-07-02T16:35:12.913Z","phase":"Phase 2","brief_title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","source_id_and_acronym":"NCT04779151 - NIRADO","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD","tags":["HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 51","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-03-26"},{"id":"43832a0d-78e8-45a5-8968-f1fa393408ec","acronym":"DORA","url":"https://clinicaltrials.gov/study/NCT05728814","created_at":"2023-02-15T18:03:03.694Z","updated_at":"2024-07-02T16:35:17.999Z","phase":"","brief_title":"DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer","source_id_and_acronym":"NCT05728814 - DORA","lead_sponsor":"Grupo Español de Investigación en Cáncer de Ovario","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2024-02-23"},{"id":"7a1267fa-f1d2-4fc1-bf7a-c4921620ad8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565378","created_at":"2022-10-04T15:57:49.680Z","updated_at":"2024-07-02T16:35:18.298Z","phase":"Phase 2","brief_title":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT05565378","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1-H","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/14/2022","start_date":" 10/14/2022","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 01/14/2028","study_completion_date":" 01/14/2028","last_update_posted":"2024-02-21"},{"id":"90764ce2-fe7f-48b7-83c9-cd61116800ca","acronym":"AZUR-2","url":"https://clinicaltrials.gov/study/NCT05855200","created_at":"2023-05-11T14:04:44.214Z","updated_at":"2024-07-02T16:35:18.713Z","phase":"Phase 3","brief_title":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","source_id_and_acronym":"NCT05855200 - AZUR-2","lead_sponsor":"GlaxoSmithKline","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Jemperli (dostarlimab-gxly) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 711","initiation":"Initiation: 08/02/2023","start_date":" 08/02/2023","primary_txt":" Primary completion: 12/15/2028","primary_completion_date":" 12/15/2028","study_txt":" Completion: 12/25/2030","study_completion_date":" 12/25/2030","last_update_posted":"2024-02-20"},{"id":"db7fe94b-d731-425b-a45c-ce7bdeaa0cf3","acronym":"AZUR-1","url":"https://clinicaltrials.gov/study/NCT05723562","created_at":"2023-02-10T15:00:32.829Z","updated_at":"2024-07-02T16:35:18.667Z","phase":"Phase 2","brief_title":"A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05723562 - AZUR-1","lead_sponsor":"GlaxoSmithKline","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 11/02/2026","primary_completion_date":" 11/02/2026","study_txt":" Completion: 10/11/2029","study_completion_date":" 10/11/2029","last_update_posted":"2024-02-20"},{"id":"0a6521fe-a965-4ddc-8722-c169de54b2ff","acronym":"PERLA","url":"https://clinicaltrials.gov/study/NCT04581824","created_at":"2021-01-18T21:51:51.753Z","updated_at":"2024-07-02T16:35:20.444Z","phase":"Phase 2","brief_title":"Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04581824 - PERLA","lead_sponsor":"GlaxoSmithKline","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK mutation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Jemperli (dostarlimab-gxly)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 243","initiation":"Initiation: 11/19/2020","start_date":" 11/19/2020","primary_txt":" Primary completion: 08/04/2022","primary_completion_date":" 08/04/2022","study_txt":" Completion: 10/20/2025","study_completion_date":" 10/20/2025","last_update_posted":"2024-02-07"},{"id":"883e16d6-d9e9-4fe7-b9df-6f7a7f6d38b9","acronym":"DEWI","url":"https://clinicaltrials.gov/study/NCT06059495","created_at":"2023-09-28T14:10:37.238Z","updated_at":"2024-07-02T16:35:20.845Z","phase":"Phase 2","brief_title":"Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study","source_id_and_acronym":"NCT06059495 - DEWI","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-02-05"},{"id":"e6eba8fe-7aa9-4c6e-9162-fce8a740dbdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016338","created_at":"2021-01-18T14:50:39.019Z","updated_at":"2025-02-25T13:12:13.736Z","phase":"Phase 2","brief_title":"Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03016338","lead_sponsor":"University Health Network, Toronto","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/06/2017","start_date":" 11/06/2017","primary_txt":" Primary completion: 01/05/2021","primary_completion_date":" 01/05/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-30"},{"id":"3564d2f5-0c6d-477b-bf48-60926e198e75","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062420","created_at":"2023-10-02T20:12:29.438Z","updated_at":"2024-07-02T16:35:22.705Z","phase":"Phase 2","brief_title":"Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT06062420","lead_sponsor":"GlaxoSmithKline","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly) • nelistotug (GSK6097608)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 09/17/2025","primary_completion_date":" 09/17/2025","study_txt":" Completion: 08/12/2027","study_completion_date":" 08/12/2027","last_update_posted":"2024-01-22"},{"id":"82013286-70fc-49b1-bd27-fd2d41b85ce4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493060","created_at":"2021-01-18T21:35:01.218Z","updated_at":"2024-07-02T16:35:22.947Z","phase":"Phase 2","brief_title":"Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04493060","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • BRCA1 • BRCA2 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/07/2023","primary_completion_date":" 12/07/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-01-19"}]